Dwayne "The Rock" Johnson, TRT, and the Ethics of Celebrity Prescription Disclosure

What Dwayne Johnson Has Actually Said About Steroids and Testosterone

Johnson's own words form the only confirmed record. Everything beyond those statements is inference, and this article labels it as such.

The 2009 MTV Interview

In a 2009 interview, Johnson told MTV: "I tried [steroids] when I was 18. Me and my buddies tried it. We didn't know what we were doing." He described experimenting briefly and stopping. That statement remains the most direct public admission he has made about anabolic steroid use. It is worth noting that recreational steroid experimentation was common in professional wrestling during the 1990s, a period extensively documented in congressional testimony and WWE's own Talent Wellness Program records [1].

Ongoing Public Speculation

Johnson's physique at age 54 (as of 2026) continues to draw scrutiny from fitness commentators, physicians on social media, and bodybuilding forums. His lean mass, vascularity, and conditioning have prompted widespread speculation about ongoing testosterone replacement therapy, human growth hormone (HGH), or both. Johnson has addressed skeptics on multiple occasions through social media, generally deflecting with humor rather than offering specific confirmations or denials. In a 2021 interview with Vanity Fair, he spoke broadly about discipline, training volume, and diet without addressing pharmacological interventions directly.

The distinction matters clinically. A man in his mid-50s maintaining 240+ pounds of lean mass at sub-15% body fat occupies a statistical outlier position. Research published in the Journal of Clinical Endocrinology & Metabolism shows that men experience roughly a 1% to 2% annual decline in total testosterone after age 30, with parallel losses in lean mass averaging 3% to 8% per decade after age 30 [2]. This does not prove pharmacological assistance. It contextualizes the physiology.

TRT: What the Clinical Evidence Actually Shows

Understanding the ethics of disclosure requires understanding what TRT is, who qualifies, and what it does. TRT is not a performance-enhancing drug regimen in the way anabolic steroid abuse is characterized, though the line can blur depending on dosing.

Diagnostic Criteria for Hypogonadism

The Endocrine Society's 2018 clinical practice guideline defines male hypogonadism as a total testosterone level below 300 ng/dL, confirmed on at least two morning samples, combined with signs or symptoms such as reduced libido, erectile dysfunction, fatigue, or loss of muscle mass [3]. The American Urological Association (AUA) uses a similar threshold of 300 ng/dL and estimates that hypogonadism affects roughly 20% to 25% of men over age 30 [4].

Standard TRT Protocols

FDA-approved testosterone formulations include intramuscular injections (testosterone cypionate or enanthate, typically 100 to 200 mg every one to two weeks), transdermal gels (AndroGel 1.62%, Testim), and subcutaneous pellets (Testopel). The goal of therapy is to restore serum testosterone to the mid-normal range (450 to 600 ng/dL), not to push levels into supraphysiological territory [3].

Supraphysiological Dosing vs. Replacement

This distinction is central to the disclosure debate. Clinical TRT aims for physiological restoration. Bodybuilding-oriented protocols often involve testosterone doses of 300 to 1,000+ mg per week, frequently stacked with compounds like nandrolone, trenbolone, or HGH at 2 to 4 IU daily. A 2014 systematic review in Annals of Internal Medicine found that testosterone therapy at replacement doses modestly improved sexual function and body composition but did not produce the dramatic muscular hypertrophy associated with supraphysiological use [5]. The Testosterone Trials (TTrials), a coordinated set of seven randomized trials enrolling 790 men aged 65 and older with testosterone levels below 275 ng/dL, showed that one year of testosterone gel treatment increased lean body mass by an average of 1.25 kg compared to placebo [6].

Put differently: standard TRT does not build a physique like Johnson's. That observation does not confirm what Johnson does or does not take. It clarifies what TRT alone can and cannot accomplish.

The Ethics of Celebrity Prescription Disclosure

The core question is straightforward: do public figures who profit from their physiques owe audiences transparency about pharmacological assistance? The answer depends on which ethical framework you apply.

Autonomy and Medical Privacy

U.S. Law is unambiguous. HIPAA protects individuals' medical information, and no statute compels public figures to disclose prescribed medications [7]. The AMA Code of Medical Ethics holds that patient confidentiality is a foundational principle, and physicians cannot disclose patient information without consent regardless of the patient's public profile [8]. From a pure autonomy standpoint, Johnson (or any celebrity) has zero legal obligation to share medication details.

The Harm Principle and Body Image

The counterargument draws on public health ethics. A 2019 study in Body Image (N=259 young men) found that exposure to muscular-ideal media images significantly increased body dissatisfaction and drive for muscularity, with effect sizes comparable to thin-ideal media exposure in women [9]. When a public figure's physique is presented as the product of discipline and training alone, audiences may internalize unrealistic standards, pursue dangerous supplement or steroid use, or develop muscle dysmorphia.

The prevalence of anabolic-androgenic steroid (AAS) use among non-competitive recreational gym-goers is estimated at 18.4% globally according to a 2023 meta-analysis published in Sports Medicine (57 studies, N=271,163) [10]. That figure has risen over the past two decades. Whether celebrity physique culture drives that increase is debated, but the association between media exposure and AAS initiation has been documented in multiple cross-sectional surveys [10].

A Middle Ground: Disclosure Without Detail

Some bioethicists have proposed a framework that separates categorical disclosure from clinical disclosure. Categorical disclosure means acknowledging the general category of pharmacological support ("I use prescribed hormone therapy under medical supervision") without revealing specific drugs, doses, or diagnoses. Clinical disclosure means sharing the full protocol. Dr. Harrison Pope, a psychiatrist at Harvard Medical School and leading researcher on muscle dysmorphia, has argued that categorical honesty from public figures would "substantially reduce the distortion of young men's body image expectations" [11]. This framework preserves medical privacy while reducing the harm of implied natural achievement.

The Endocrine Society's 2018 guideline itself notes: "Clinicians should inform patients of the ongoing societal pressure that may arise from unrealistic portrayals of male body composition in media" [3]. The guideline does not address celebrity disclosure directly, but it acknowledges the clinical relevance of media-driven body expectations.

Johnson's Position in the Broader Celebrity TRT Field

Johnson is not the only public figure facing these questions. He is the most visible.

Comparisons to Other Public Acknowledgments

Joe Rogan has discussed his TRT use openly on his podcast, describing a protocol of testosterone cypionate at approximately 200 mg per week along with HGH. Sylvester Stallone was arrested in Australia in 2007 for importing 48 vials of HGH and subsequently spoke publicly about using hormone therapy for anti-aging purposes. Arnold Schwarzenegger has acknowledged steroid use during his competitive bodybuilding career in interviews dating back to the 1970s.

Each case illustrates a different disclosure model. Rogan's approach is the most transparent: specific drug, approximate dose, medical supervision acknowledged. Schwarzenegger's is historical admission without current-use specificity. Johnson's falls somewhere between non-denial and non-confirmation.

Why Johnson's Case Draws More Scrutiny

Three factors amplify scrutiny. First, Johnson's commercial brand is built substantially on his physique. His Project Rock fitness line, Under Armour partnership, and film roles (many requiring shirtless scenes with visible muscularity) tie his income directly to his body. Second, his social media presence (over 400 million Instagram followers as of 2026) amplifies his influence on body norms to a degree that smaller-audience figures like Rogan do not match. Third, his age. Maintaining his current lean mass and body fat percentage at 54 places increasing physiological demands that the age-related testosterone decline data make harder to reconcile with unassisted training [2].

None of these factors create a legal obligation. They do intensify the ethical argument for categorical disclosure.

What Clinicians Should Tell Patients Who Ask About Celebrity Physiques

The clinical encounter is where the rubber meets the road. Patients, particularly men aged 25 to 45, frequently cite celebrity physiques when discussing body composition goals or requesting testosterone prescriptions.

Screening for Realistic Expectations

The Endocrine Society explicitly recommends against prescribing testosterone to men who do not meet diagnostic criteria for hypogonadism, regardless of their physique goals [3]. A 2017 JAMA study found that between 2001 and 2013, testosterone prescriptions in the U.S. Increased approximately 3-fold, with nearly 25% of men who initiated therapy not having a testosterone level checked beforehand [12]. This prescribing pattern suggests that cultural demand, partly driven by celebrity physique culture, may be outpacing clinical indication.

Discussing the Natural Ceiling

Clinicians can use validated models to set expectations. The Fat-Free Mass Index (FFMI), a height-normalized measure of lean mass, has a widely cited natural ceiling of approximately 25.0 kg/m² for drug-free men, based on research by Kouri et al. Published in Clinical Journal of Sports Medicine [13]. Men with FFMIs above 25.0 are statistically more likely to be using anabolic agents. Johnson's estimated FFMI (calculated from publicly reported height of 6'5" and weight of approximately 260 lbs at roughly 14% body fat) falls near 27 to 28. That figure is above the natural ceiling, though individual genetic variation and measurement error make any single FFMI estimate imprecise.

Monitoring and Safety in Prescribed TRT

For patients who do meet criteria, the AUA recommends monitoring hematocrit (target below 54%), PSA, lipid panels, and liver function at baseline, 3 to 6 months, and then annually [4]. Testosterone therapy carries documented risks including erythrocytosis, sleep apnea exacerbation, and cardiovascular events in certain populations. The TRAVERSE trial (N=5,246 men aged 45 to 80 with cardiovascular risk factors) published in The New England Journal of Medicine in 2023 found that transdermal testosterone was noninferior to placebo for major adverse cardiovascular events (HR 0.99, 95% CI 0.81 to 1.21), but did show a higher incidence of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone group [14].

The Disclosure Gap and Public Health Literacy

The gap between what celebrities disclose and what their audiences assume has measurable consequences.

Survey Data on Perception

A 2020 survey published in the International Journal of Environmental Research and Public Health (N=542 male gym-goers aged 18 to 35) found that 67.3% of respondents believed that celebrity physiques were achievable without pharmacological assistance [15]. Among those who held this belief, AAS use in the prior 12 months was 2.1 times higher than among respondents who acknowledged the likely role of PEDs (OR 2.1, 95% CI 1.4 to 3.2) [15]. The causal direction is uncertain, but the association is consistent across multiple studies.

What Transparency Could Change

If high-profile figures like Johnson adopted categorical disclosure, the potential public health benefit is difficult to quantify but directionally clear. Reducing the perceived gap between "natural" and pharmacologically assisted physiques could lower AAS initiation rates among young men, decrease muscle dysmorphia prevalence (estimated at 10% of male gym-goers per DSM-5 adjacent criteria) [11], and improve the quality of clinical conversations about testosterone between patients and providers.

No single celebrity's disclosure will solve a systemic issue. But the scale of Johnson's influence (400M+ social followers, billions in box-office revenue tied to physical roles) means his choices carry outsized weight in shaping public perception.

Clinicians counseling men on testosterone therapy should directly address the gap between celebrity physiques and physiological norms, using FFMI benchmarks and the TTrials data to anchor expectations in evidence rather than aspiration [6][13].